Autopsy report · NCT01053507

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

“Enrollment rate was slower than anticipated.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 6 months before it stopped.
• 23 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Cady, Roger, M.D.

Sponsor type

University, hospital or other

Conditions

Post-Traumatic Headache

Interventions

sumatriptan/naproxen sodium; Placebo

Participants

23

Sites

3

Countries

United States

Trials that died the same way

• Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
  “Slower than anticipated enrollment” (87% match in meaning)
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
  “Slower than expected enrollment” (85% match in meaning)
• Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route
  “Slow rate of enrollment” (83% match in meaning)
• CT in Calcified Coronary Arteries With Photon Counting Detector
  “Enrollment rate too slow to reach anticipated number of participants.” (80% match in meaning)
• Customized Contrast Media Dose Clinical Trial
  “Slow enrollment.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.